Literature DB >> 21457682

QT interval duration and dispersion in children and adolescents treated with ziprasidone.

Christoph U Correll1, Johnny D Lops, Vicki Figen, Anil K Malhotra, John M Kane, Peter Manu.   

Abstract

OBJECTIVE: To assess the incidence of symptoms (palpitations, syncope) and electrocardiographic signs (increased QT duration and dispersion) of an increased risk of torsades de pointes in youth treated with ziprasidone.
METHOD: Data for this study were collected as part of a prospective, observational, mixed inpatient and outpatient cohort study of youth who were administered antipsychotic treatment for the first time. For this study, we focus on 29 patients (mean ± SD age 15.3 ± 2.9 years) receiving ziprasidone (112.8 ± 50.6 mg/d; range, 20-240) for 99.3 ± 108.7 days. All patients had normal electrocardiograms (ECGs) and no serious medical illness at baseline. Patients had a mean of 2.7 ± 1.3 (median = 3; range, 1-7; total = 49) follow-up ECGs performed monthly for 3 months and every 3 months thereafter, with concurrent blood ziprasidone level measurements. Heart rate-corrected QT interval (QTc) duration and dispersion were measured manually in ≥ 6 ECG leads. QTc > 450-millisecond or ≥ 60-millisecond increase and QTc dispersion > 100 milliseconds were considered abnormal. The study was conducted from December 2001 to September 2007.
RESULTS: No patient reported syncope or symptomatic arrhythmias. Seven patients (24.1%) developed ECG abnormalities; 5 had peak QTc durations > 450 milliseconds, and 2 had peak QTc dispersion > 100 milliseconds. The baseline-to-peak QTc duration increased by 22.9 ± 21 milliseconds (P < .0001). The baseline-to-peak QTc dispersion increased by 6.1 ± 31.4 milliseconds (P = .30). The peak QTc duration and dispersion occurred after 47.6 ± 46.0 and 60.4 ± 73.2 treatment days, respectively. Baseline-to-peak QTc duration and dispersion changes were not correlated with ziprasidone dose (P = .65) or plasma levels (P = .50).
CONCLUSIONS: Ziprasidone was associated with a dose- and level-independent, significant prolongation of QTc duration in one-quarter of youth. However, prolongation of QTc dispersion was nonsignificant, and no patient experienced concomitant abnormal prolongation of both QTc duration and QTc dispersion. The dissociation between prolonged QTc duration and dispersion suggests low arrhythmogenic potential in youth with normal baseline ECGs. © Copyright 2011 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21457682      PMCID: PMC3319445          DOI: 10.4088/JCP.10m05990yel

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  23 in total

1.  Torsades de pointes associated with ziprasidone.

Authors:  Thomas W Heinrich; Lee A Biblo; John Schneider
Journal:  Psychosomatics       Date:  2006 May-Jun       Impact factor: 2.386

Review 2.  Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes.

Authors:  Christoph U Correll
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2008-01       Impact factor: 8.829

3.  Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).

Authors:  Brian L Strom; Sybil M Eng; Gerald Faich; Robert F Reynolds; Ralph B D'Agostino; Jeremy Ruskin; John M Kane
Journal:  Am J Psychiatry       Date:  2010-11-01       Impact factor: 18.112

Review 4.  Long QT syndrome: reduced repolarization reserve and the genetic link.

Authors:  D M Roden
Journal:  J Intern Med       Date:  2006-01       Impact factor: 8.989

Review 5.  Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.

Authors:  Peter M Haddad; Ian M Anderson
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder.

Authors:  Joseph Biederman; Eric Mick; Thomas Spencer; Meghan Dougherty; Megan Aleardi; Janet Wozniak
Journal:  Bipolar Disord       Date:  2007-12       Impact factor: 6.744

7.  QT dispersion in nonsustained ventricular tachycardia and coronary artery disease.

Authors:  F Bogun; K K Chan; M Harvey; R Goyal; M Castellani; M Niebauer; E Daoud; K C Man; S A Strickberger; F Morady
Journal:  Am J Cardiol       Date:  1996-02-01       Impact factor: 2.778

8.  Ziprasidone in adolescents with autism: an open-label pilot study.

Authors:  Richard P Malone; Mary Anne Delaney; Susan B Hyman; Jacqueline R Cater
Journal:  J Child Adolesc Psychopharmacol       Date:  2007-12       Impact factor: 2.576

9.  New Generation Antipsychotic Drugs and QTc Interval Prolongation.

Authors:  W VictorR Vieweg
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-10

10.  QT dispersion and components of the QT interval in ischaemia and infarction.

Authors:  P D Higham; S S Furniss; R W Campbell
Journal:  Br Heart J       Date:  1995-01
View more
  8 in total

Review 1.  Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

Authors:  Marc De Hert; Johan Detraux; Ruud van Winkel; Weiping Yu; Christoph U Correll
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

2.  Need for a more developmental perspective: QTc prolongation under psychotropic medication.

Authors:  Veit Roessner; Nicole Wolff; Stefan Ehrlich; Robert Waltereit
Journal:  Eur Child Adolesc Psychiatry       Date:  2017-08       Impact factor: 4.785

Review 3.  Safety and pharmacokinetics of atypical antipsychotics in children and adolescents.

Authors:  Silvio Caccia
Journal:  Paediatr Drugs       Date:  2013-06       Impact factor: 3.022

4.  The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders.

Authors:  Jason G Ho; Randall L Caldwell; Christopher J McDougle; Danielle K Orsagh-Yentis; Craig A Erickson; David J Posey; Kimberly A Stigler
Journal:  J Child Adolesc Psychopharmacol       Date:  2012-07-31       Impact factor: 2.576

Review 5.  QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.

Authors:  Mehrul Hasnain; W Victor R Vieweg
Journal:  CNS Drugs       Date:  2014-10       Impact factor: 5.749

Review 6.  Metabolic consequences of second-generation antipsychotics in youth: appropriate monitoring and clinical management.

Authors:  Rebecca A Krill; Sanjiv Kumra
Journal:  Adolesc Health Med Ther       Date:  2014-09-26

Review 7.  What's in the pipeline? Drugs in development for autism spectrum disorder.

Authors:  Min Sung; Chee Hon Chin; Choon Guan Lim; Hwee Sen Alvin Liew; Chau Sian Lim; Espérance Kashala; Shih-Jen Weng
Journal:  Neuropsychiatr Dis Treat       Date:  2014-02-20       Impact factor: 2.570

Review 8.  Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatrists.

Authors:  Simone Pisano; Gennaro Catone; Stefania Veltri; Valentina Lanzara; Marco Pozzi; Emilio Clementi; Raffaella Iuliano; Maria Pia Riccio; Sonia Radice; Massimo Molteni; Annalisa Capuano; Antonella Gritti; Giangennaro Coppola; Annarita Milone; Carmela Bravaccio; Gabriele Masi
Journal:  Ital J Pediatr       Date:  2016-05-21       Impact factor: 2.638

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.